• HealthCare21
    Where is personalised medicine in industry heading?

On our 21st birthday, our team at HealthCare21 covered the significant advancements within the healthcare sector that occurred over the past 21 years. We will now be posting 21 developments that will be shaping the future of medical communications and healthcare delivery.

1. With ever-increasing understanding of disease pathways and how inter-patient variability can play a role in the way drugs interact with them, personalised or precision medicine is becoming an urgent mission for regulatory agencies overseeing public health, and a natural trajectory for Pharma. With nearly 7,000 medicines in development, 74 percent of which are potentially first-in-class, patients have more reasons to be optimistic than ever before. Medicines are being developed across dozens of therapeutic areas – including cancer, diabetes, cardiovascular, Alzheimer’s disease and more.


A rolling survey of 16 biopharma companies shows an 87% mean increase in pharmacogenomics-based therapy research investment over the last 5 years. All the surveyed companies said their discovery strategy involved biomarkers and/or targeted therapies, but having a biomarker/companion diagnostic was not a requirement to move into downstream clinical development. A database of annotated labels for drugs approved by four major drug-regulatory agencies (in the European Union, Japan, Canada and the United States) currently lists almost 200 drugs with pharmacogenomic information. While oncology remains a key drug target, almost two-thirds of companies report working on neuropsychiatric disorders, and close to one-half focussed on cardiology and immunological or inflammatory conditions, while metabolic diseases and infectious diseases are similar.


Where is personalised medicine in industry heading? Nature Reviews Drug Discovery Β· October 2015


Share this article